Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447509 | 0.88 | TRPV1 (0.73) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL14423770 | 0.88 | TRPV1 (0.69) | TRPV1KIT | |
| SCHEMBL4262793 | 0.86 | TRPV1 (0.82) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL3712104 | 0.85 | TRPV1 (0.80) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL6430919 | 0.83 | TRPV1 (0.77) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL4269392 | 0.81 | TRPV1 (0.73) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL4262251 | 0.81 | HSD17B10 (0.71) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL6435440 | 0.80 | TRPV1 (0.71) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL4265025 | 0.80 | TRPV1 (0.78) | TRPV1NPSR1HSD17B10CA12CA1 | |
| SCHEMBL4865985 | 0.79 | TRPV1 (0.79) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885NPSR1 90/4885HSD17B10 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.